With the success of these two immunology drugs, AbbVie now anticipates $24.7 billion in combined sales in 2025, raising its previously issued guidance by close to $900 million.

AbbVie (NYSE: ABBV) is a global biopharmaceutical company long synonymous with its blockbuster drug, Humira. While the drug's ...

AbbVie's Diversification Strategy Cushions Venetoclax MDS Blow. Jun. 17, 2025 6:42 AM ET AbbVie Inc. (ABBV) ... AbbVie remains very active in immunology, oncology, and neuroscience.

Dublin, Nov. 25, 2024 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: AbbVie Inc. - 2024" company profile has been added to ResearchAndMarkets.com's offering. The report provides ...

AbbVie gains control of an in vivo CAR-T therapy that could overcome limitations with currently approved autologous ...

AbbVie raises profit forecast despite potential tariffs on demand for new immunology drugs Drugmaker plans to build four new U.S. sites CEO outlines strategies to mitigate tariff impacts April 25 ...

AbbVie is scheduled to report full-year earnings on Jan. 31, but management said at the J.P. Morgan Healthcare Conference last week that the company grew in fiscal year 2024 despite falling sales ...

“Focusing on AbbVie’s immunology segment, Humira’s global revenue of $2.814 billion declined 30% year-over-year given formidable biosimilar competition,” Brown wrote. “AbbVie is doing an excellent job ...

AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience strategy and boosting competition for Cobenfy.

AbbVie Inc , a global biopharmaceutical powerhouse, has recently filed its 10-Q report on August 7, 2024. This SWOT analysis delves into the company's financials, strategic acquisitions, and ...

RS Investments, an investment management company, released its “RS Large Cap Value Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here.